Roche appeals, fights for new Accutane judge 
Published: March 11, 2013
Tags: Accutane, birth defects, DRI, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, recusal
Continuing in its efforts to find a new judge for the thousands of Accutane cases pending in New Jersey state court, Hoffman-La Roche filed notice to appeal a decision by presiding Judge Carol E. Higbee not to recuse herself in the case.
N.J. judge refuses to recuse herself from Accutane cases
Published: March 4, 2013
Tags: Accutane, birth defects, DRI, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, recusal, suicide
The state judge overseeing Accutane mass tort litigation in New Jersey has denied Hoffmann- La Roche’s motion asking that she recuse herself.
Hoffmann-La Roche asks for Accutane judge’s recusal
Published: December 28, 2012
Tags: Accutane, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, mass tort litigation, recusal
Drug maker Hoffmann- La Roche has asked for the recusal of the New Jersey judge overseeing the Accutane mass tort litigation, asserting that Judge Carol E. Higbee is siding unfairly with plaintiffs who allege injuries from the acne drug.
Accutane plaintiffs won’t get $13M
Published: August 9, 2012
Tags: Accutane, failure to warn, learned intermediary doctrine, product liability
Product liability plaintiffs could not show that stronger warnings for the acne drug Accutane would have prevented their injuries, the New Jersey Appellate Division has ruled.
Accutane warning ruled adequate
Published: August 2, 2012
Tags: Accutane, Hoffmann-La Roche, inflammatory bowel disease, product liability
Pharmaceutical company Hoffmann-La Roche adequately warned a user of the acne drug Accutane of the risk of developing inflammatory bowel disease, a U.S. District Court in Florida has ruled in granting summary judgment.
Accutane maker appeals $18M verdict over bowel disease
By:
Sylvia Hsieh
Published: July 17, 2012
Tags: Accutane, drug litigation, IBD, Roche
Drug maker Roche has appealed an $18 million jury verdict that found Accutane responsible for causing inflammatory bowel disease in two of four plaintiffs.
Reglan most litigated drug of 2011, latest ranking says
Published: June 7, 2012
Tags: Accutane, adverse events, Avandia, Bayer, Chantix, Coumadin, drug litigation, FDA, Food and Drug Administration, GlaxoSmithKline, Hoffman-LaRoche, Institute for Safe Medication Practices, Johnson & Johnson, Levaquin, Pfizer, Pradaxa, prescription drugs, Reglan, Wyeth, Yasmin, Yaz
The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.
Accutane litigation grows
By:
Correy Stephenson
Published: March 7, 2012
Tags: Accutane, drug litigation, multi-district litigation
After more than a decade, the litigation against Hoffman-LaRoche, the maker of the acne drug Accutane, continues to grow.
More than 7,000 cases are currently on file in multi-district litigation consolidated in New Jersey state court, and both sides continue to vigorously litigate with no settlement negotiations in sight.
New Jersey court upholds $25 million Accutane verdict
Published: September 28, 2011
Tags: Accutane, IBD, inflammatory bowel disease
Denying a defense motion for remittitur or new trial, a New Jersey judge has affirmed a jury’s $25.16 million award to an Alabama man who suffered from inflammatory bowel disease as a result of taking the acne medication Accutane.
Accutane verdicts: $2 million for one plaintiff out of three
By:
Correy Stephenson
Published: April 22, 2011
Tags: Accutane, Crohn’s disease, drug litigation, failure to warn, Hoffman-LaRoche, IBD, inflammatory bowel disease
In a trio of cases tried together against Hoffman-LaRoche, the maker of Accutane, jurors awarded just one of the plaintiffs suffering from inflammatory bowel disease $2.1 million.
